A recent study found that reducing PD‐L1 expression can enhance the effectiveness of PD‐1 monoclonal antibody treatment by improving the blocking of the PD‐1/PD‐L1 interaction, thereby reducing immune evasion, alleviating immune suppression, and modulating the tumor microenvironment.[28, 32] Bioinformatics analysis revealed a correlation between PP1A expression, immune infiltration, and PD‐L1 expression. The gene discussed is CD274; the disease is neoplasm.